| Title |
Two cases of Alzheimer's disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, December 2012
|
| DOI | 10.2147/ndt.s37688 |
| Pubmed ID | |
| Authors |
Takemi Kimura, Junichi Takamatsu |
| Abstract |
Rivastigmine, galantamine, and memantine, in addition to donepezil, which has been on the market over 10 years, have been available for the treatment of Alzheimer's disease (AD) since 2011 in Japan, leading a new stage in the medical treatment of AD. We studied two AD patients showing sudden deterioration of behavioral and psychological symptoms of dementia (BPSD) associated with switching from rivastigmine to donepezil after the clinical trial of rivastigmine. In the patients, rivastigmine seemed to be more beneficial than donepezil for the control of BPSD. Although It was not obvious whether their different responses to the two cholinesterase inhibitors were due to the different pharmacological profiles, ie, the presence of inhibition of butyrylcholinesterase in rivastigmine, a particular cholinesterase inhibitor might be more effective in particular AD cases. Further investigations are needed to confirm the difference, and to identify the measures for selecting the most appropriate medication for each AD patient. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 31 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 4 | 13% |
| Student > Doctoral Student | 4 | 13% |
| Student > Master | 4 | 13% |
| Student > Ph. D. Student | 3 | 10% |
| Lecturer | 2 | 6% |
| Other | 4 | 13% |
| Unknown | 10 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Psychology | 5 | 16% |
| Medicine and Dentistry | 4 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Chemistry | 2 | 6% |
| Neuroscience | 2 | 6% |
| Other | 4 | 13% |
| Unknown | 12 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 January 2013.
All research outputs
#20,823,121
of 25,584,565 outputs
Outputs from Neuropsychiatric Disease and Treatment
#2,293
of 3,120 outputs
Outputs of similar age
#227,375
of 286,730 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#20
of 26 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,120 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,730 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.